Bluejay Diagnostics Announces New Funding
Bluejay Diagnostics, Inc. (NASDAQ: BJDX), a pioneering medical diagnostics company, has taken a significant step forward in its growth journey by securing a $4.5 million private placement. This funding will bolster the company’s efforts in developing near-patient solutions specifically designed for critical care settings.
Details of the Private Placement
The recent agreement allows for the sale of 2,250,000 shares of common stock, or pre-funded warrants in lieu of common shares. Additionally, the Series F warrants included in the offering will give investors the opportunity to purchase up to 4,500,000 more shares at an exercise price of $1.75. The purchase price is set at $2.00 per share, and this private placement is executed under Nasdaq rules aimed at complying with market regulations.
Utilization of Proceeds
Importantly, the gross proceeds from this offering are anticipated to fund several key activities. Bluejay intends to utilize the net proceeds to support its research and development initiatives and take essential steps toward obtaining FDA approval. The company is dedicated to enhancing its products and processes, which serve an essential role in improving patient outcomes.
Exclusive Placement Agent
Rodman and Renshaw LLC has been appointed as the exclusive placement agent for this offering, ensuring the private placement is conducted smoothly and efficiently. This collaboration signifies the confidence placed in Bluejay Diagnostics as it advances its mission.
Understanding the Securities Offerings
This securities offering is structured under Section 4(a)(2) of the Securities Act of 1933, which regulates how common stock and warrants can be sold. The shares offered in this placement, along with those underlying the warrants, are exempt from registration under applicable state securities laws.
Future Expectations
Bluejay Diagnostics aims to file a resale registration statement covering the sold securities, paving the way for future trading. This proactive measure demonstrates Bluejay's commitment to compliance and transparency. Investors can look forward to further announcements as the company progresses.
About Bluejay Diagnostics
Founded to enhance patient care, Bluejay Diagnostics focuses on advanced medical diagnostic solutions. Its flagship product, the Symphony System, is a rapid, near-patient testing system tailored for sepsis triage and monitoring. Designed to deliver precise results within approximately 20 minutes, the IL-6 Test for sepsis empowers healthcare professionals to make informed decisions swiftly.
Innovative Solutions for Critical Care
As the healthcare landscape continues to evolve, Bluejay remains at the forefront, committed to developing technologies that enhance the efficacy and efficiency of critical care diagnostics. The company is driven by a vision to improve outcomes for patients suffering from sepsis and other time-sensitive conditions.
Contact Information
For investor inquiries or further information about Bluejay Diagnostics, please reach out via the following:
Investor Contact:
Investor Relations
Bluejay Diagnostics, Inc.
ir@bluejaydx.com
Website: www.bluejaydx.com
Frequently Asked Questions
What is the recent funding amount for Bluejay Diagnostics?
Bluejay Diagnostics has successfully secured $4.5 million through a private placement.
What will the funds be used for?
The proceeds will primarily be utilized to support FDA approval processes and enhance research and development efforts.
Who is the placement agent for this offering?
Rodman and Renshaw LLC is acting as the exclusive placement agent for the private offering.
What is the purpose of the Series F warrants?
The Series F warrants allow investors to purchase additional shares at an exercise price of $1.75 each.
How does Bluejay Diagnostics contribute to patient care?
Bluejay focuses on providing rapid and effective diagnostic solutions, specifically for sepsis management, substantially improving patient outcomes.
